INTRODUCTION
The abnormal pregnancy, hydatidiform mole (HM) represents a disorder of genomic imprinting, a phenomenon whereby genes are monoallelically expressed from the maternally or paternallyderived copy of the gene, the other being transcriptionally silent. HM are classified on the basis of histopathology and genetic origin as partial (PHM) or complete (CHM) (1) . The majority of HM develop from conceptuses with an excess of paternal to maternal genomes and consequently result from the global misexpression of imprinted genes. PHM generally arise from a dispermic conception (2-4) which is consequently triploid, with one maternal and two paternal contributions to the nuclear genome. In CHM, maternal chromosomes are generally absent. The conception is diploid, but androgenetic, in that all 46 chromosomes are paternal in origin (5, 6) . Thus trophoblastic hyperplasia, common to both androgenetic CHM (AnCHM) and PHM, is associated with the overexpression of paternally transcribed genes. Foetal development, although abnormal, is present in PHM which have a maternal contribution to the genome. Lack of foetal development in AnCHM is therefore attributed to the absence of maternally transcribed genes in these pregnancies.
CHM may originate by dispermy (7) but are more likely to be monospermic, arising from fertilization of a functionally anucleate egg by a single sperm whose pronucleus undergoes endoreduplication to produce a diploid chromosome complement (5, 6) . A third and much rarer type of CHM is also diploid, but biparental (BiCHM), rather than androgenetic, in origin (8) (9) (10) (11) (12) . Unlike AnCHM, which generally occur sporadically, BiCHM often occur in patients who have a history of multiple CHM arising in different conceptions (12, 13) and more specifically, in the affected women of families in which two or more individuals have molar pregnancies (12, 14, 15) . In cases, known to be familial, the condition appears to exhibit an autosomal recessive mode of inheritance. Although the gene(s) involved and the nature of the underlying mutation have yet to be elucidated, linkage studies have identified a region on 19q13.3-13.4 in which the gene for familial BiCHM resides (14) .
BiCHM exhibit all the histopathologic hallmarks of classic AnCHM, including trophoblast hyperplasia and atypia, lack of embryonic development and abnormal villous mesenchyme.
Indeed, BiCHM and AnCHM are histologically indistinguishable (13) , requiring DNA analysis to discriminate between them. BiCHM, like AnCHM, also have a significant risk of persistent trophoblastic disease (15, unpublished data) . Thus, despite their distinct genetic origins, BiCHM and AnCHM are strikingly similar in all phenotypes, suggesting that BiCHM are also the result of abnormal imprinting.
To explore this possibility we examined the expression of p57 KIP2 , the product of the imprinted (maternally expressed) gene CDKN1C (16), in BiCHM. This protein has been previously shown to be strongly expressed in placenta and its differential pattern of expression in HM and non-molar placental villi has been well-characterized. p57
KIP2 is readily detectable in cytotrophoblast and villous mesenchyme of PHM and non-molar gestations, but is markedly underexpressed in these cell types in CHM, consistent with the absence of a maternal genome in the latter (17, 18) . In previous studies, the genetic origin of the CHM examined was not determined for most cases. However, given the rarity of BiCHM, it is unlikely that BiCHM were included in these studies. Here we evaluate p57 KIP2 expression in a series of genetically defined BiCHM, including molar tissue from two sisters with familial BiCHM.
RESULTS

Genotyping of chromosome 19q in family CX01
Homozygosity mapping (19) of DNA from six members of family CX01 with 14 highly polymorphic short tandem repeats established a 15 cM region of homozygosity on 19q13.3-13.4 extending from D19S924 to the telomere of 19q in the two sisters with recurrent BiCHM. This region of homozygosity was not found in either of two sisters who had normal offspring and no molar pregnancies (Fig. 1 ).
p57
KIP2 expression in genetically defined hydatidiform moles One AnCHM (case 8), one PHM (case 9) and ten BiCHM (cases 1-7) were evaluated for p57 KIP2 expression using immunohistochemistry (Table 1 ). In the PHM strong p57 KIP2 nuclear staining was observed in a significant percentage of CT and VM cells ( Fig. 2A1-2 ). This pattern of p57 KIP2 expression was indistinguishable from that previously observed, by us (18) in non-CHM gestations, including PHM, normal placenta and spontaneous abortions. In contrast, the classic AnCHM showed lack of p57 KIP2 expression in CT and VM ( Fig. 2B1-2 ), consistent with previous results for CHM (17, 18) . In the CHM, maternal decidua or intervillous trophoblast islands served as internal positive controls for p57 KIP2 immunostaining. Strikingly all ten cases of BiCHM were negative for p57 KIP2 expression in CT and VM in all villi, whereas internal controls were uniformly positive ( Fig. 2C1-2) . Consequently, the expression pattern of p57 KIP2 in BiCHM is identical to that of AnCHM, despite their distinct genetic origins. 
DISCUSSION
The importance of genomic imprinting in normal development is underscored by the growing number of pathological conditions known to result from dysfunction of imprinted genes. Among these conditions, PHM and AnCHM are remarkable in that they result from an excess of paternal to maternal genomes and are thus likely to result from global misexpression of imprinted genes. Consistent with this view, the imprinted, paternally expressed loci ZNF127, ZAC/PLAGL and HYMAI have been shown to have a paternal methylation imprint in CHM (21-23) while other studies have shown abnormal expression of the imprinted, maternally transcribed genes H19 (24, 25) and CDKN1C (17,18) in these conceptuses. These results are consistent with the absence of a maternal nuclear genome in AnCHM.
A rare variant of CHM has occasionally been described with an apparently normal chromosome complement, being diploid with both a paternal and maternal contribution to the nuclear genome. These BiCHM are associated with recurrent CHM (12, 13) and are familial in at least some cases (12, 15) . By analogy with AnCHM, which is histologically indistinguishable from BiCHM, the gene for familial BiCHM is likely to affect imprinting of a number of different genes. Since only females are affected and the condition may occur with more than one partner (13), the defect is likely to be in a gene involved in the establishment and/or maintenance of normal imprints in the ovum. In a recent study of a single case of BiCHM (26) , bisulphite sequencing of a number of imprinted genes on different chromosomes showed them to have a paternal, rather than a maternal, epigenotype on both alleles, consistent with a failure to establish maternal imprints within the ovum.
In this study we have examined expression of the maternally transcribed gene, CDNK1C. We have shown expression of p57 KIP2 to be abnormal in all ten BiCHM examined, with an androgenetic pattern of expression rather than that seen in other types of biparental conceptuses. Thus we have shown that abnormal imprinting is a common mechanism underlying the development of BiCHM. In AnCHM, both overexpression of paternally transcribed genes and loss of maternally transcribed genes would be predicted. Thus loss of p57 KIP expression in androgenetic tissues is likely to result from an absence of the maternally transcribed allele (17) . More recently it has been shown that expression of Cdnk1c, not only requires a maternally derived allele, but is also dependent on a maternal imprint during oogenesis (27) . It has now been clearly demonstrated that, in mice, a number of genes, including Cdnk1c, are regulated in cis by the maternally methylated, imprinting control centre, KvDMR1 (28, 29) . Silencing of p57 KIP2 in BiCHM is consistent with both alleles of KvDMR1 remaining demethylated and provides further evidence that the underlying defect in BiCHM is a global failure to set the maternal imprint during oogenesis.
It is unclear whether loss of p57 KIP2 plays a role in the development of CHM. Cdkn1c deficient mice show abnormal cell proliferation and differentiation leading to a variety of developmental defects (30) including placentomegaly (31) demonstrating that p57 KIP2 plays a role in the regulation of trophoblastic development in mice. In man, mutations in CDNK1C, or loss of p57 KIP2 expression, occur in BeckwithWiedemann syndrome (32) in which the placenta shares pathological features, such as villous hydrops, with hydatidiform moles (33) . However, although less marked than in CHM, molar development also occurs in PHM in which p57 KIP2 is apparently normal. In addition, we have identified a single case of CHM, pathologically indistinguishable from other CHM, which, although androgenetic for other chromosomes, was trisomic for 11p15.5 and positive for p57 KIP2 staining, (D. Castrillon et al., manuscript in preparation). These observations suggest that downregulation of p57 KIP2 is not essential for the development of CHM.
Since tumourigenesis may be associated with the loss of cell cycle regulators such as cyclin dependent kinases, loss of p57 KIP2 may play a role in the very high incidence of choriocarcinoma which develop after CHM compared to other types of pregnancy (34) . In support of this, p57
KIP2 expression was undetectable in 3 cases of choriocarcinoma (17) . Despite the small number of BiCHM described, the development of trophoblastic tumours has been observed in several cases (15, unpublished data) . BiCHM, like AnCHM, appear to be a greater risk factor for trophoblastic tumour development than normal pregnancies. Larger series of BiCHM need to be examined to determine the relative risk of post-mole tumours after AnCHM or BiCHM.
The gene involved in BiCHM has not yet been identified although it is unusual in that it appears to control imprinting of genes on a number of chromosomes, in trans and is, therefore, unlike previously described imprinting control centres that act locally, in cis (32, 35) . In mice, loss of maternal methylation imprints in their oocytes has been reported in females homozgous for a deletion of the methyltransferase related gene product, Dnmt3L (36) . Progeny of these mice die before mid-gestation, show defects which are common consequences of abnormalities in extraembryonic tissues and lack expression of a number of genes dependent on a maternal imprint including Cdnk1c (36). They therefore share a number of characteristics with CHM. However, sequencing of all 12 exons of DNMT3L (37), revealed no mutations in either of the two sisters with recurrent BiCHM or two patients with sporadic BiCHM, described in this report (unpublished data). In man DNMT3L maps to chromosome 21q22.3 and is unlikely to be the critical gene mutated in familial BiCHM since a candidate locus has been mapped to 19q13.3-13.4 by linkage and homozygosity mapping (14, 15) . In this report we describe a fourth family with recurrent BiCHM with a large region of homozygosity across the19q13.3-13.4 region segregating with the disease gene. Further studies of families with this rare condition will enable the identification of one or more genes with a critical role in the control of imprinting.
Identification of genes critical in the abnormal development associated with molar pregnancies is complicated by paternal disomy of the whole nuclear genome and, in AnCHM, loss of the entire maternal chromosome complement. BiCHM however, have an equal maternal and paternal contribution to the genome and provide a unique opportunity to investigate the basic mechanisms underlying genomic imprinting and the role of imprinted genes in the early development of embryonic and extraembryonic tissues and in tumour development.
MATERIALS AND METHODS
Patient material
Patients with recurrent molar pregnancies were identified from patients registered with the Trophoblastic Tumour Screening and Treatment Unit at Charing Cross Hospital. Histopathological review of molar tissue was performed on routine sections stained with haematoxylin and eosin, to distinguish PHM from CHM, by at least two independent pathologists (38) . Where available, parental blood and molar tissue were genotyped, as previously described, to confirm the diagnosis of PHM and, in case of CHM, distinguish between CHM of androgenetic or biparental origin (13) . Briefly, DNA was prepared from parental blood and molar tissue and, in each case, at least 6 informative markers (Human Genome Database, http//www.gdb.org) examined in DNA from the patient, her partner and the molar tissue. HM were classified as AnCHM if at least two markers in the HM had no maternal allele and all other markers were consistent with a paternal origin. HM were classified as PHM if three alleles were present at two or more loci and the additional allele was paternal in origin. CHM were classified as BiCHM if both a maternal and a paternal marker were present for each locus tested and there was no evidence of trisomy.
Six patients with recurrent molar pregnancies of biparental origin were identified (Table 1) . One patient had a sister with a single BiCHM. The five other patients had no other affected family members. Expression of p57 KIP2 was examined in tissue from a single molar pregnancy in each of the two sisters (cases 1 and 2), a single molar pregnancy from two other patients with recurrent BiCHM (cases 3 and 4) and two different pregnancies in the remaining three patients (cases 5-7). Tissue from an AnCHM (case 8) and a PHM (case 9), obtained from patients with recurrent CHM of androgenetic origin and recurrent PHM, respectively, were also examined as controls.
Genotyping of family with BiCHM
Two sisters with BiCHM in this study were the progeny of a consanguineous marriage. They had two further sisters both of whom had normal pregnancies and no history of HM. The four sisters and their parents (family CX01) were genotyped, as previously described (13) , with 14 highly polymorphic microsatellite markers located within the 19q13.3-13.4 region (Fig. 1) . The most likely haplotypes for the six individuals were derived by minimizing the number of recombination events.
Antibodies and immunohistochemistry
Immunocytochemistry was performed with mouse monoclonal antibodies against the p57 KIP2 protein (NeoMarkers/Lab Vision Corporation, CA) on paraffin-embedded formalin-fixed tissue. Antigen retrieval was performed at 93 C in 10 mM sodium citrate buffer pH 6.0 for 30 minutes with a 10 minute cooldown.
The detection system was Envision (Dako Corporation, CA) with diaminobenzidine as the chromogen; slides were counterstained with hematoxylin. Only distinct nuclear staining of similar intensity to that observed in internal controls was scored as positive. In all cases, the presence or absence of nuclear staining was assessed in villous mesenchyme, cytotrophoblast, extravillous trophoblast and decidua, blinded to the original diagnosis and independent of the H&E histologic appearance. For a case to be scored as positive for p57 KIP2 expression, staining was required in a significant proportion of villous mesenchyme (VM) and cytotrophoblast (CT) cells (>10% but typically around 30%). Sporadic p57 KIP2 expression in VM and CT cells (<1% of total cells) was not considered positive.
